- Home Page | LITFULO® (ritlecitinib) | Safety Info
LITFULO (ritlecitinib) is a prescription medicine used to treat severe alopecia areata in adults and adolescents 12 years and older
- Litfulo: Uses, Dosage, Side Effects, Warnings - Drugs. com
Litfulo (ritlecitinib) and Olumiant (baricitinib) are both oral medications that may be used to treat certain autoimmune conditions Olumiant is a Janus kinase (JAK) inhibitor, and Litfulo inhibits JAK3 and the TEC kinase family
- LITFULO- ritlecitinib capsule - Pfizer
LITFULO (ritlecitinib) capsules are formulated with ritlecitinib tosylate, a kinase inhibitor Ritlecitinib tosylate is a white to off white to pale pink solid which is freely soluble in water
- label - Food and Drug Administration
LITFULO is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older (1) Limitations of Use: Not recommended for use in combination with other JAK • For dosage interruption for certain adverse reactions, see Full Prescribing Information (2 4)
- Litfulo (ritlecitinib): Uses, Side Effects, Interactions . . . - WebMD
Find patient medical information for Litfulo (ritlecitinib) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings
- Home | LITFULO® (ritlecitinib) capsules HCP Site | Safety Info
Discover LITFULO®, the only FDA-approved treatment for severe alopecia areata in both adults and adolescents as young as 12 See safety info
- Ritlecitinib: First Approval - PMC
Ritlecitinib (LITFULO™), an orally administered kinase inhibitor, is being developed by Pfizer for the treatment of alopecia areata, vitiligo, ulcerative colitis and Crohn’s disease On 23 June 2023, ritlecitinib received approval in the USA for the
- Safety Side Effects | LITFULO (ritlecitinib) | Safety Info
Learn important info about potential side effects for LITFULO® and safety for this once-daily prescription for people ages 12+ with severe alopecia areata
|